脑源性神经营养因子（BDNF）作为脑胶质瘤潜在生物标志物的系统评价与Meta分析

Brain-Derived Neurotrophic Factor (BDNF) as a Potential Biomarker in Brain Glioma: A Systematic Review and Meta-Analysis.

作者信息

Hasani Fatemeh, Masrour Mahdi, Khamaki Sina, Jazi Kimia, Ghoodjani Erfan, Teixeira Antonio L

机构信息

Gastroenterology and Hepatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

Neuroscience Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

出版信息

Brain Behav. 2025 Jan;15(1):e70266. doi: 10.1002/brb3.70266.

BACKGROUND

This systematic review and meta-analysis evaluates peripheral and CNS BDNF levels in glioma patients.

METHODS

Following PRISMA guidelines, we systematically searched databases for studies measuring BDNF in glioma patients and controls. After screening and data extraction, we conducted quality assessment, meta-analysis, and meta-regression.

RESULTS

Eight studies were included. Meta-analysis showed significantly reduced plasma BDNF levels in glioma patients versus controls (SMD: -1.0026; 95% CI: [-1.5284, -0.4769], p = 0.0002). High-grade gliomas had lower plasma BDNF (p = 0.0288). Tissue BDNF levels were higher in glioma patients (SMD: 1.9513; 95% CI: [0.7365, 3.1661], p = 0.0016) and correlated with tumor grade (p = 0.0122). Plasma BDNF levels negatively correlated with patient age (p = 0.0244) and positively with female percentage (p = 0.0007).

CONCLUSION

BDNF is a promising biomarker in glioma, showing significant changes in plasma and tissue levels correlating with tumor grade, patient age, and gender.

背景

本系统评价和荟萃分析评估了胶质瘤患者外周和中枢神经系统脑源性神经营养因子（BDNF）水平。

方法

按照PRISMA指南，我们系统检索数据库以查找测量胶质瘤患者和对照组BDNF的研究。经过筛选和数据提取后，我们进行了质量评估、荟萃分析和荟萃回归。

结果

纳入八项研究。荟萃分析显示，与对照组相比，胶质瘤患者血浆BDNF水平显著降低（标准化均数差：-1.0026；95%置信区间：[-1.5284, -0.4769]，p = 0.0002）。高级别胶质瘤患者血浆BDNF水平较低（p = 0.0288）。胶质瘤患者组织BDNF水平较高（标准化均数差：1.9513；95%置信区间：[0.7365, 3.1661]，p = 0.0016），且与肿瘤分级相关（p = 0.0122）。血浆BDNF水平与患者年龄呈负相关（p = 0.0244），与女性比例呈正相关（p = 0.0007）。